Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 12/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 6/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789599 | 0.87 | CA2 (0.37) | MEN1GAAKMT2ACTSKCA2 | |
| SCHEMBL29822881 | 0.83 | CTSK (0.46) | MEN1GAAKMT2ASLC15A1CTSK | |
| SCHEMBL27511249 | 0.81 | SLC15A1 (0.58) | SLC15A1CTSKCTSS | |
| SCHEMBL5967148 | 0.81 | SLC15A1 (0.58) | SLC15A1CTSKCTSS | |
| SCHEMBL7163456 | 0.80 | CTSK (0.46) | CTSKCA2CA1CA7CTSS | |
| SCHEMBL31525047 | 0.80 | CTSK (0.46) | CTSKCA2CA1CA7CTSS | |
| SCHEMBL27546163 | 0.80 | TDP1 (0.40) | MEN1GAAKMT2ACTSKCA2 | |
| SCHEMBL11187682 | 0.80 | TDP1 (0.40) | MEN1GAAKMT2ACTSKCA2 | |
| SCHEMBL5816674 | 0.79 | GNAI3 (0.47) | MEN1GAAKMT2ASLC15A1MAOA | |
| SCHEMBL28259715 | 0.79 | GNAI3 (0.47) | MEN1GAAKMT2ASLC15A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234274-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| EP-1532124-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004000825-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234274-A1 | Novel Compounds | CTSS, CTSB, CTSF | MEN1 3526/4885GAA 51/4885KMT2A 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.